Pulmopharma ApS was established back in November 2014. The technology itself was a spinoff from the parent company called LiquidVanity ApS, which holds the extensive basic patent for the technology which is the basis for our novel drug – the Puldium™.

Both LiquidVanity and PulmoPharma were founded by the same team: Dan Nyenstad Mønster, CEO and entrepreneur with extensive experience in idea development and application methodologies. Per Bendix Jeppesen, Associate Prof., PhD. at Aarhus University, Department of Clinical Medicine, has many years of experience in drug development as well as a basic knowledge of chemistry, and has been involved in several international drug developments as a clinical manager. Torben Ballegaard Sørensen, has a long career in business development and has held several board positions such as the Electrolux, LEGO, Bang & Olufsen, Pandora, Egmont Foundation and others.

The technology is developed and based on combating pathogenic microorganisms and was initially based on removing these pathogenic microorganisms in delicate textiles at low temperatures, but technology proved to be so unique that it can be used for other purposes, including combating invasive Aspergillus.

Later, other investors joined the firm.